Effect of fluoxetine on pharmacokinetics of ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 12, 1998, Pages 3107-3112

  Ouellet, Daniele ^a,b   Hsu, Ann ^b   Qian, Jiang ^b   Lamm, Janet E ^b   Cavanaugh, John H ^b   Leonard, John M ^b   Granneman, G Richard ^b  

^a PFIZER INC   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; FLUOXETINE; RITONAVIR; SEROTONIN UPTAKE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; FLUOXETINE; GENOTYPE; HALF-LIFE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR;

EID: 0031759626     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Abbott Laboratories. 1996. Norvir package insert. Abbott Laboratories. Abbott Park, Ill.
2. Altamura, A. C., A. R. Moro, and M. Percudani. 1994. Clinical pharmacokinetics of fluoxetine. Clin. Pharmacokinet. 26:201-214.
3. Baumann, P., and B. Rochat. 1995. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int. Clin. Psychopharmacol. 10(Suppl. 1):15-21.
4. Bergstrom, R. F., A. L. Peyton, and L. Lemberger. 1992. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin. Pharmacol. Ther. 51:239-248.
5. Brøsen, K., and E. Skjelbo. 1991. Fluoxetine and norfluoxetine are potent inhibitors of P450IID6 - the source of the sparteine/debrisoquine oxidation polymorphism. Br. J. Clin. Pharmacol. 32:136-137.
6. Crewe, H. K., M. S. Lennard, G. T. Tucker, F. R. Woods, and R. E. Haddock. 1992. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br. J. Clin. Pharmacol. 34:262-265.
7. Danner, S. A., A. Carr, J. M. Leonard, L. M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, A. G. Aguado, J. G. De Lomas, R. Delgado, J. C. C. Borleffs, A. Hsu, J. M. Valdes, C. A. B. Boucher, and D. A. Cooper. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333: 1528-1533.
8. Dista Products Co. and Eli Lilly & Co. 1996. Prozac package insert. Dista Products Co. and Eli Lilly & Co., Indianapolis, Ind.
9. Fieller, E. 1954. Some problems in interval estimation. J. R. Statistical Soc. B 16:175-185.
10. Fulton, B., and D. McTavish. 1995. Fluoxetine - an overview of its pharmacodynamics and pharmacokinetic properties and review of its therapeutic efficacy in obsessive-compulsive disorder. Cent. Nerv. Syst. Drugs 3(4):305-322.
11. Greenblatt, D. J., S. H. Preskorn, M. M. Cotreau, W. D. Horst, and J. S. Harmatz. 1995. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin. Pharmacol. Ther. 52(5):479-489.
12. Hsu, A., G. R. Granneman, G. Witt, C. Locke, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Liu, J. P. Decourt, J. B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
13. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X.-P. Kong, N. E. Wideburg, A. Saldivar, L. Ruiz, W. M. Kati, H. L. Sham, T. Robins, K. D. Stewart, A. Hsu, J. J. Plattner, J. M. Leonard, and D. W. Norbeck. 1995. ABT-538 is a potent inhibitor of human immunodefiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
14. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 227:423-431.
15. Lebel, M., J. Turgeon, F. Vallée, P.-M. Bélanger, F. Paquet, and B. A. Hamelin. 1995. Genetic determinant of sertraline (S) and fluoxetine (F) disposition in 20 healthy volunteers. Pharm. Res. 12(Suppl.):S-374.
16. Markowitz, M., M. Saag, W. G. Powderly, A. M. Hurley, A. Hsu, J. M. Valdes, D. Henry, F. Sattler, A. La Marca, J. M. Leonard, and D. D. Ho. 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N. Engl. J. Med. 333:1534-1539.
17. Marsh, K. C., E. Eiden, and E. McDonald. 1997. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 704:307-313.
18. Rasmussen, B. B., J. Mäenpää, O. Pelkonen, S. Loft, H. E. Poulsen, J. Lykkesfeldt, and K. Brøsen. 1995. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol. 39:151-159.
19. Robins, T., and J. Plattner. 1993. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquired Immune Defic. Syndr. 6: 162-170.
20. Schmider, J., D. J. Greenblatt, L. L. Von Molke, J. S. Harmatz, and R. I. Shader. 1995. N-demethylation of amitriptyline in vitro: role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 275:592-597.
21. Stevens, J. C., and S. A. Wrighton. 1993. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J. Pharmacol. Exp. Ther. 266(2):964-971.
22. Von Moltke, L. L., D. J. Greenblatt, J. Schmider, J. S. Harmatz, and R. I. Shader. 1995. Metabolism of drugs by cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin. Pharmacokinet. 29(Suppl. 1):33-44.
23. Wang, J.-P., and J. D. Unadkat. 1995. Human P450 isoforms involved in the formation of the active metabolites of (R)-and (S)-fluoxetine, p. 385. ISSX Proceedings, 4th International ISSX Meeting.